SIRT1 and triple-A syndrome: Xu et al. were the first to demonstrate that LiCl could prevent the development of AAA by regulating the glycogen synthase kinase 3 beta/sirtuin 1/nuclear factor kappa B (GSK3β/SIRT1/NF-κB) pathway, inhibiting inflammation, superoxide production and elastin degradation (Figure 6C; Table 2) (Xu et al., 2021).